Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA VPRIV Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    VPRIV (velaglucerase)

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA Medicare Advantage coverage and prior authorization for VPRIV (velaglucerase) enzyme replacement therapy in members with Gaucher disease. Coverage applies when applicable diagnosis and confirmation requirements are met and no therapy exclusions apply.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyVPRIV (velaglucerase)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateNot scheduled
    Key ActionPrecertification is required for VPRIV coverage; providers should use the HMSA medical specialty drug policy fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Gaucher disease types covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Authorization duration
    RequiredPrecertification before coverage
    Enzyme assay or genetic testingDiagnostic confirmation

    Covered Gaucher Disease Types

    Gaucher disease type 1

    Authorization of 12 months may be granted when the following diagnosis confirmation requirement is met.

    Type 1 Gaucher disease coverage

    • Diagnostic confirmation

      • The diagnosis was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.
      • The diagnosis was confirmed by genetic testing.

    Gaucher disease type 2

    Authorization of 12 months may be granted when the following diagnosis confirmation requirement is met.

    Type 2 Gaucher disease coverage

    • Diagnostic confirmation

      • The diagnosis was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.
      • The diagnosis was confirmed by genetic testing.

    Gaucher disease type 3

    Authorization of 12 months may be granted when the following diagnosis confirmation requirement is met.

    Type 3 Gaucher disease coverage

    • Diagnostic confirmation

      • The diagnosis was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.
      • The diagnosis was confirmed by genetic testing.

    Authorization and Documentation Requirements

    Prior Authorization

    Submit precertification before VPRIV coverage

    Precertification is required for VPRIV coverage. Refer to the HMSA medical specialty drug policy website for the fax form.

    Documentation Required

    Document diagnostic confirmation

    For initial requests, make beta-glucocerebrosidase enzyme assay or genetic testing results supporting the diagnosis available upon request.

    • The testing must support the Gaucher disease diagnosis.
    • An enzyme assay must demonstrate deficient beta-glucocerebrosidase (glucosidase) enzyme activity, or genetic testing must confirm the diagnosis.

    VPRIV and Gaucher Disease

    VPRIV (velaglucerase) is an enzyme replacement therapy (ERT) indicated for the long-term treatment of type 1 Gaucher disease. HMSA also covers compendial treatment of Gaucher disease types 2 and 3 when the diagnosis is confirmed. ERT may improve systemic manifestations of Gaucher disease, including anemia, thrombocytopenia, hepatomegaly, splenomegaly, and skeletal disease; however, it does not reverse brain damage associated with type 2 disease.

    Key Definitions

    Confirmed Gaucher disease
    DefinitionA diagnosis supported by deficient glucocerebrosidase (glucosylceramidase) enzyme activity or identification of biallelic pathogenic variants in GBA1.
    Enzyme evidenceDeficient enzyme activity may be demonstrated in peripheral blood leukocytes or other nucleated cells.
    Genetic evidenceIdentification of biallelic pathogenic variants in GBA1 (formerly GBA) supports the diagnosis.
    Enzyme replacement therapy (ERT)
    DefinitionLong-term treatment that replaces the deficient enzyme in patients with Gaucher disease.
    VPRIV indicationVPRIV is indicated for long-term enzyme replacement therapy for patients with type 1 Gaucher disease.

    Initial Therapy

    Initial therapy: Gaucher disease type 1

    Authorization of 12 months may be granted for treatment of Gaucher disease type 1 when the diagnosis is confirmed.

    Diagnostic confirmation

    • Gaucher disease type 1 is confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.
    • Gaucher disease type 1 is confirmed by genetic testing.

    Initial therapy: Gaucher disease type 2

    Authorization of 12 months may be granted for treatment of Gaucher disease type 2 when the diagnosis is confirmed.

    Diagnostic confirmation

    • Gaucher disease type 2 is confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.

    Continuation and Reauthorization

    No previous authorization

    Members without previous authorization or precertification, including new members and members currently receiving treatment without prior authorization, must meet the criteria for initial approval.

    Continuation without previous authorization: The member meets the applicable initial therapy criteria for the requested indication.

    Applies when there is no previous authorization or precertification.

    Reauthorization

    Authorization for 12 months may be granted to members who were previously authorized by HMSA/CVS when all of the following criteria are met.

    • Current treatment: The member is currently receiving therapy with the requested medication.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyVPRIV (velaglucerase)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateNot scheduled
    Key ActionPrecertification is required for VPRIV coverage; providers should use the HMSA medical specialty drug policy fax form.
    SourceLink
    On This Page
    Covered Gaucher Disease TypesAuthorization and Documentation RequirementsVPRIV and Gaucher DiseaseKey DefinitionsInitial TherapyContinuation and Reauthorization
    Denial Risk

    Unconfirmed Gaucher disease risks denial

    Coverage may be denied when the Gaucher disease diagnosis is not confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    • The confirmation requirement applies to Gaucher disease types 1, 2, and 3.
    Denial Risk

    Meet all reauthorization criteria

    Reauthorization may be denied unless the member is currently receiving VPRIV, the medication is being used for an indication listed in the coverage criteria, and the member is receiving benefit from therapy.

    • Benefit means no inadequate response and no intolerable adverse events from therapy.
    • Authorization may be granted for 12 months when all reauthorization criteria are met.
    Clinical effectsERT can improve anemia and thrombocytopenia, reduce hepatomegaly and splenomegaly, and ameliorate skeletal damage.
  1. Gaucher disease type 2 is confirmed by genetic testing.
  2. Initial therapy: Gaucher disease type 3

    Authorization of 12 months may be granted for treatment of Gaucher disease type 3 when the diagnosis is confirmed.

    Diagnostic confirmation

    • Gaucher disease type 3 is confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity.
    • Gaucher disease type 3 is confirmed by genetic testing.
    Covered indication:
    The requested medication is being used to treat an indication listed in the coverage criteria section.
  3. Clinical benefit: The member is receiving benefit from therapy, defined as not experiencing an inadequate response or any intolerable adverse events from therapy.